FDA fast tracks another possible COVID-19 vaccine

Posted at 6:04 AM, Nov 10, 2020
and last updated 2020-11-10 08:56:31-05

TAMPA, Fla. — The Food and Drug Administration has given another possible COVID-19 vaccine fast track designation.

The vaccine, produced by Novavax, will begin phase 3 clinical trials by the end of November.

RECOMMENDED: FDA grants emergency use authorization to Eli Lilly's experimental COVID-19 antibody drug

Fast track designation means it could get regularly approval or emergency authorization faster than normal.

The federal government’s operation Warp Speed is giving Novavax $1.6 billion to run its trials.

The company’s vaccine is made by growing synthetic versions of the coronavirus spike protein in moth cells.

RECOMMENDED: Tampa Bay area doctors look ahead to promise for COVID-19 vaccine, state's vaccination plan

A plant-based compound that boosts immune response is also part of it.

The vaccine joins 4 others that have been fast-tracked.